Affibody AB

Affibody AB is a leading biotechnology company focused on developing innovative biotherapeutics. Utilizing next-generation technology platforms, including Affibody® molecules and Albumod™, Affibody AB is dedicated to advancing medical science and patient care. The company's commitment to research and development drives its mission to create impactful treatments for a range of diseases. Located in Haga, Stockholm, at Scheeles väg 2, Affibody AB operates with a focused experimental medicine model, ensuring efficient and effective progress in its clinical programs.

With multiple clinical-stage programs, Affibody AB is at the forefront of therapeutic innovation. These programs target critical areas such as psoriasis and B-cell driven autoimmune diseases, as well as diagnostic imaging for metastatic breast cancer. Affibody AB’s strategic approach and cutting-edge technologies position it as a key player in the biopharmaceutical industry, continually striving to improve patient outcomes and address unmet medical needs.

Affibody AB is dedicated to making significant contributions to the biotechnology field through its ongoing research and development efforts. The company’s location in Stockholm fosters a collaborative environment conducive to scientific advancement and innovation. We invite the manager of Affibody AB to create a customized and exclusive company showcase and product listing on our platform, highlighting the unique strengths and offerings of Affibody AB.